Stockscreener 앱 받기
2.96
2.95%
-0.09
시간 외 거래:
3.01
0.05
+1.69%
전일 마감가:
$3.05
열려 있는:
$3.03
하루 거래량:
189.46K
Relative Volume:
1.12
시가총액:
$100.71M
수익:
$210.00K
순이익/손실:
$-10.40M
주가수익비율:
-9.3998
EPS:
-0.3149
순현금흐름:
$-6.88M
1주 성능:
+5.71%
1개월 성능:
+19.35%
6개월 성능:
-9.76%
1년 성능:
-7.79%
1일 변동 폭
$2.87
$3.08
1주일 범위
$2.74
$3.4842
52주 변동 폭
$2.32
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
명칭
Anixa Biosciences Inc
전화
408-708-9808
주소
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.96 | 103.77M | 210.00K | -10.40M | -6.88M | -0.3149 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | Maxim Group | Buy |
| 2022-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2021-04-12 | 개시 | H.C. Wainwright | Buy |
Anixa Biosciences Inc 주식(ANIX)의 최신 뉴스
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Trial to Highest Dose Cohort - HLTH
Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial - Moomoo
Anixa doses first patient in highest cohort of ovarian trial - Investing.com
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level. - Bitget
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date - PR Newswire
ANIXAnixa Biosciences Inc Revenue Breakdown - Finviz
Here's why you should add ANIX stock to your portfolio now - MSN
ANIX Assumed by D. Boral Capital -- Rating Maintained at Buy - GuruFocus
Anixa Biosciences Price Target Maintained With a $10.00/Share by D. Boral Capital - Moomoo
Anixa Biosciences secures Korean patent for breast cancer vaccine - Yahoo Finance
Anixa Biosciences Granted First Korean Patent for its Breast Can - GuruFocus
Anixa receives South Korean patent for breast cancer vaccine - Investing.com
Anixa Biosciences (ANIX) Secures Patent for Breast Cancer Vaccine Technology - GuruFocus
Anixa receives South Korean patent for breast cancer vaccine By Investing.com - Investing.com South Africa
Anixa Secures Patent for Breast Cancer Vaccine in South Korea - Intellectia AI
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 - PR Newswire
Anixa Biosciences, Inc. Actuals & Estimates (NASDAQ:ANIX) - TradingView
Anixa Biosciences, Inc. Actuals & Estimates (DUS:CY71) - TradingView
Price to sales forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView
Anixa presents breast cancer vaccine, ovarian CAR-T trial data - Investing.com UK
Anixa Biosciences (ANIX) Showcases Immunotherapy Progress at Key Symposium - GuruFocus
Anixa presents breast cancer vaccine, ovarian CAR-T trial data By Investing.com - Investing.com Australia
Enterprise value to revenue forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView
Anixa Biosciences stock falls despite Phase 1 trial updates By Investing.com - Investing.com Nigeria
Anixa Biosciences stock falls despite Phase 1 trial updates - Investing.com
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium - Barchart.com
Enterprise value to EBIT forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView
Price to earnings forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView
ANIX Forecast — Price Target — Prediction for 2027 - TradingView
Anixa Biosciences, Inc. Actuals & Estimates (SWB:CY71) - TradingView
Here's Why You Should Add ANIX Stock to Your Portfolio Now - The Globe and Mail
Anixa Biosciences, Inc. (ANIX) Latest Stock News & Headlines - Yahoo Finance
Anixa Biosciences Inc (ANIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
H.C. Wainwright Maintains Anixa Biosciences(ANIX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Penny Stocks To Watch For Growth In June 2026 - Sahm
Anixa Biosciences Inc (ANIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Anixa Biosciences Inc (ANIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Anixa Biosciences Inc (ANIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anixa Biosciences Inc (ANIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Anixa Biosciences Inc (ANIX) Institutional Confidence - TradingKey
Anixa Biosciences Inc (ANIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Anixa Biosciences Inc (ANIX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Anixa Biosciences Inc (ANIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Buying: Titterton Lewis H Jr Increases Stake in Anixa Bi - GuruFocus
Anixa Biosciences (ANIX) director adds 2,836 shares in open-market buy - Stock Titan
Anixa Biosciences Gains Over 5% as Biotech Sector Shows Renewed Interest (ANIX)OBV Trend Line - newsline.com
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc - GuruFocus
Anixa Biosciences CEO Amit Kumar buys $52,500 in company stock By Investing.com - Investing.com India
Anixa Biosciences Inc (ANIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anixa Biosciences Inc 주식 (ANIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KUMAR AMIT | Chief Executive Officer |
Jun 12 '26 |
Buy |
2.50 |
21,000 |
52,500 |
630,812 |
| Baskies Arnold M | Director |
Jan 28 '26 |
Buy |
3.04 |
10,000 |
30,400 |
135,000 |
| Titterton Lewis H jr | Director |
Dec 15 '25 |
Option Exercise |
2.92 |
16,000 |
46,720 |
969,334 |
| KUMAR AMIT | Chief Executive Officer |
Oct 30 '25 |
Option Exercise |
2.92 |
200,000 |
584,000 |
779,925 |
| Titterton Lewis H jr | Director |
Jul 31 '25 |
Buy |
3.08 |
10,000 |
30,800 |
953,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
1.17%
2.48%
자본화:
|
볼륨(24시간):